Increased PT is an essential feature of COVID-19 and is a risk factor for disease severity and poor prognosis
In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available
Its thought to involve small changes in the part of the nervous system that regulates heart rate, rather than any direct electrical effect on the heart
GLP-1Rs are expressed in the pancreas, intestinal intraepithelial lymphocytes, myocardium, adipose tissue, kidney, liver, blood vessels, lungs and in the CNS.2,3 Although GLP-1 is known for its incretin effect, which it shares with glucose-dependent insulinotropic peptide (GIP), the intake-regulating action, essential for its efficacy against obesity, occurs through its interaction with receptors located in the CNS.1,5 The GLP-1 peptide can reach the central nervous system (CNS) via peripheral vagal afferents, which transmit its action through the nodose ganglion to the nucleus tactus solitarius (NTS)
[DOI] [PubMed] [Google Scholar] 62.Deacon C.F
10.1016/j.neuron.2006.08.023 49 HsuR.TaylorJ
.webp)
